Satralizumab

萨特利珠单抗

Report date: 2026/05/21 17:57:07
First In Class

Base Information

Drug NameSatralizumab
Drug Alias Name沙利珠单抗sapelizumab沙贝利组单抗sapelizumabumSatralizumab-mwge +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionIL-6 receptor antagonists
TargetsIL-6 receptor
Therapy Area/IndicationsMyelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseGraves OphthalmopathyEncephalitis +[10] 
Global Approved IndicationsNeuromyelitis Optica
Approved Indications in ChinaNeuromyelitis Optica
Original Approved Country/TerritoryJapan
Original Approved Date2020/06/29
Country/TerritoryCzechiaBulgariaCanada +[37] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesChugai Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInternational University of Health and WelfareChugai Pharmaceutical Co LtdF. Hoffmann-La Roche Ltd +[7] 
Inactive CompaniesUniversity Of Florida
Active IndicationsMyelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseGraves OphthalmopathyEncephalitis +[7] 
Inactive IndicationsSubarachnoid HemorrhageBrain IschemiaMyasthenia Gravis

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBankKEGG